P 03277

Drug Profile

P 03277

Alternative Names: P03277

Latest Information Update: 13 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Guerbet
  • Class Gadolinium-containing contrast agents
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II CNS disorders; Hepatocellular carcinoma

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Hepatocellular carcinoma (Diagnosis) in France (IV) (NCT02973516)
  • 22 Nov 2016 Guerbet plans a phase II trial for Hepatocellular carcinoma (Diagnosis) in USA and France (NCT02973516)
  • 01 Mar 2016 Phase-II clinical trials in CNS disorders (Diagnosis) in Hungary (IV) (EudraCT2014-003576-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top